Trial Profile
PegIntron [peginterferon alfa-2b]/REBETOL [ribavirin] Combination Therapy Designated Drug Use Investigation -Investigation on the Safety and Efficacy of PegIntron and REBETOL Combination Therapy in Patients With Chronic Hepatitis C Excluding Those With 'IFN [interferon] Naive Low Viral Load and Genotype 1 and High Viral Load
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms COMPLETED
- Sponsors Merck Sharp & Dohme Corp.
- 28 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Aug 2008 New trial record.